Literature DB >> 24424387

Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening.

Yuting Huang1, Baohui Ju1, Jing Tian1, Fenghua Liu1, Hu Yu1, Huiting Xiao1, Xiangyu Liu1, Wenxin Liu1, Zhi Yao2, Quan Hao1.   

Abstract

Cancer stem cells, with unlimited self-renewal potential and other stem cell characteristics, occur in several types of cancer, including ovarian cancer (OvC). Although CSCs can cause tumor initiation, malignant proliferation, relapse and multi-drug resistance, ways to eliminate them remain unknown. In the present study, we compared ovarian cancer stem cell (OVCSC) expression profiles in normal ovarian surface epithelium and ovarian cells from patients with advanced disease to identify key pathways and specific molecular signatures involved in OVC progression and to prescreen candidate small-molecule compounds with anti-OVCSC activity. Comparison of genome-wide expression profiles of OvC stemness groups with non-stemness controls revealed 6495, 1347 and 509 differentially expressed genes in SDC, SP1 and SP2 groups, respectively, with a cut-off of fold-change set at >1.5 and P<0.05. NAB1 and NPIPL1 were commonly upregulated whereas PROS1, GREB1, KLF9 and MTUS1 were commonly downregulated in all 3 groups. Most differentially expressed genes consistently clustered with molecular functions such as protein receptor binding, kinase activity and chemo-repellent activity. These genes regulate cellular components such as centrosome, plasma membrane receptors, and basal lamina, and may participate in biological processes such as cell cycle regulation, chemoresistance and stemness induction. Key Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways such as ECM receptor, ErbB signaling, endocytosis and adherens junction pathways were enriched. Gene co-expression extrapolation screening by the Connectivity Map revealed several small-molecule compounds (such as SC-560, disulfiram, thapsigargin, esculetin and cinchonine) with potential anti-OVCSC properties targeting OVCSC signature genes. We identified several key CSC features and specific regulation networks in OVCSCs and predicted several small molecules with potential anti-OVCSC pharmacological properties, which may aid the development of OVCSC-specific drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24424387     DOI: 10.3892/or.2014.2976

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

Review 1.  The Krüppel-like factors in female reproductive system pathologies.

Authors:  Rosalia C M Simmen; Melissa E Heard; Angela M Simmen; Maria Theresa M Montales; Meera Marji; Samantha Scanlon; John Mark P Pabona
Journal:  J Mol Endocrinol       Date:  2015-02-05       Impact factor: 5.098

2.  Cancer Stem Cells: An Ever-Hiding Foe.

Authors:  Jacek R Wilczyński
Journal:  Exp Suppl       Date:  2022

3.  Spheres from cervical cancer cells display stemness and cancer drug resistance.

Authors:  Huan Liu; Haijuan Wang; Chunxiao Li; Tingting Zhang; Xiting Meng; Ying Zhang; Haili Qian
Journal:  Oncol Lett       Date:  2016-07-20       Impact factor: 2.967

4.  The transcriptional co-activator NCOA6 promotes estrogen-induced GREB1 transcription by recruiting ERα and enhancing enhancer-promoter interactions.

Authors:  Zhangwei Tong; Yonghong Liu; Xiaobin Yu; Jarrod D Martinez; Jianming Xu
Journal:  J Biol Chem       Date:  2019-11-19       Impact factor: 5.157

5.  Loss of MTUS1 Expression Is Associated With Poor Prognosis in Patients With Gallbladder Carcinoma.

Authors:  Jongmin Sim; Yeseul Kim; Hyungsung Kim; Seongsik Bang; Seungyun Jee; Seongun Park; Su-Jin Shin; Kiseok Jang
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

6.  Thalidomide inhibits proliferation and epithelial-mesenchymal transition by modulating CD133 expression in pancreatic cancer cells.

Authors:  Congying Chen; Ge Yu; Wenqin Xiao; Miao Xing; Jianbo Ni; Rong Wan; Guoyong Hu
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

Review 7.  The mitochondrial landscape of ovarian cancer: emerging insights.

Authors:  Pallavi Shukla; Keshav K Singh
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

8.  CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.

Authors:  Ran Liu; Huiting Wei; Peng Gao; Hu Yu; Ke Wang; Zheng Fu; Baohui Ju; Meng Zhao; Shangwen Dong; Zhijun Li; Yifeng He; Yuting Huang; Zhi Yao
Journal:  Oncotarget       Date:  2017-06-13

9.  Docosahexaenoic acid and disulfiram act in concert to kill cancer cells: a mutual enhancement of their anticancer actions.

Authors:  Yang Jiao; Bethany N Hannafon; Roy R Zhang; Kar-Ming Fung; Wei-Qun Ding
Journal:  Oncotarget       Date:  2017-03-14

10.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.